Long-term partial remission with capecitabine/trastuzumab in a patient with metastatic breast cancer following progression on trastuzumab alone

Breast Care

Volumn 7, Issue 1, 2012, Pages 45-47

  Uleer, Christoph ^a,e   Yazdan Pourfard, Jasmin ^a   Holland, Bernhard ^a   Bürrig, Karl Friedrich ^b   Moisidis Tesch, Christina ^c   Von Minckwitz, Gunter ^d  

^a St Bernward Hospital   (Germany)

^b Pathology Institute   (Germany)

^c Gynecologic Practice   (Germany)

^d German Breast Group C/o GBG Research GmbH   (Germany)

^e SP Gynäkologische Onkologie Gynäkologisch Onkologische Praxisgemeinschaft ^*  (Germany)

Author keywords

Breast cancer; Capecitabine; Metastasized; Trastuzumab

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; IBANDRONIC ACID; TRASTUZUMAB;

ADD ON THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; HAND FOOT SYNDROME; HUMAN; LUNG METASTASIS; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PRIORITY JOURNAL;

EID: 84858663060     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000336536     Document Type: Article

References (8)

1. Viani GA, Afonso SL, Stefano EJ, et al.: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007;7:153.
2. Marty M, Cognetti F, Maraninchi D, et al.: Randomized ph II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered as first line treatment: the M770001 study group. J Clin Oncol 2005;23:4265-4274. (Pubitemid 46207001)
3. Vogel CL, Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in the first line treatment of her2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
4. Stemmler HJ, Kahlert S, Siekiera W, Untch M, et al.: Prolonged survival of patients receiving trastuzumab beyond disease progression for her 2 overexpressing metastatic breast cancer. Onkologie 2005; 28:582-586. (Pubitemid 41513144)
5. Cancello G, Montagna E, Agostino D, et al.: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008;10:R60.
6. Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
7. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, et al.: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 2007;6:2065-2072. (Pubitemid 47052497)
8. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, et al.: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5655. (Pubitemid 39180938)